Rosiglitazone, an ingredient in popular Type II diabetes drugs such as Avandia, Avandamet, and Avandaryl, has been shown to increase the risk of a heart attack and other cardiovascular problems. The U.S. Food and Drug Administration will soon restrict access to these medicines by requiring patients and their doctors to enroll in a special program to use them.<\/p>\n
After mid-November of this year, patients will not be able to get these medicines at a neighborhood pharmacy. The Avandia-Rosiglitazone Medicines Access Program will allow patients to get the medicine by certified, mail-order pharmacies. This special program is for patients who have successfully used these medicines and cannot control their blood sugar with other anti-diabetic medicines.<\/p>\n
\u201cThere are multiple and conflicting signals of cardiovascular ischemic risk related to rosiglitazone,\u201d said Dr. Janet Woodcock, the Director of the Center for Drug Evaluation and Research. \u201cThe current cardiovascular safety database for Rosiglitazone does not provide an assurance (more…)<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Rosiglitazone, an ingredient in popular Type II diabetes drugs such as Avandia, Avandamet, and Avandaryl, has been shown to increase the risk of a heart attack and other cardiovascular problems. The U.S. Food and Drug Administration will soon restrict access…<\/span><\/p>\n